Phosphorothioate oligodeoxynucleotides exert a sequence-independent cytoprotective effect against human immunodeficiency virus type 1 (HIV-1). We now report that phosphorodithioate-containing oligodeoxycytidines are very potent inhibitors of HIV-1 reverse transcriptase in vitro, as they exhibit an increasing inhibitory effect with length and number of phosphorodithioate internucleotide linkages. This inhibitory effect can be at least 30-fold greater with phosphorodithioate oligodeoxycytidine than for the corresponding phosphorothioate analog of similar length. In cell culture, phosphorodithioate oligodeoxycytidines are active inhibitors of syncytia formation and effectively inhibit de novo infection of target cells by HIV-1. Moreover, comparative experiments show that a deoxycytidine phosphorodithioate 14-mer is as effective an inhibitor of de novo infection as a phosphorothioate-containing 28-mer. Such potent inhibition by oligomers of relatively short length makes dithioate analogs an additional class of potential therapeutic agents against acquired immunodeficiency syndrome.
ABSTRACT
Phosphorothioate oligodeoxynucleotides exert a sequence-independent cytoprotective effect against human immunodeficiency virus type 1 (HIV-1). We now report that phosphorodithioate-containing oligodeoxycytidines are very potent inhibitors of HIV-1 reverse transcriptase in vitro, as they exhibit an increasing inhibitory effect with length and number of phosphorodithioate internucleotide linkages. This inhibitory effect can be at least 30-fold greater with phosphorodithioate oligodeoxycytidine than for the corresponding phosphorothioate analog of similar length. In cell culture, phosphorodithioate oligodeoxycytidines are active inhibitors of syncytia formation and effectively inhibit de novo infection of target cells by HIV-1. Moreover, comparative experiments show that a deoxycytidine phosphorodithioate 14-mer is as effective an inhibitor of de novo infection as a phosphorothioate-containing 28-mer. Such potent inhibition by oligomers of relatively short length makes dithioate analogs an additional class of potential therapeutic agents against acquired immunodeficiency syndrome.
Over the past several years, oligodeoxynucleotides and their analogs have been reported to inhibit viral replication and the expression of oncogenes in cell culture (1, 2). Although the pioneering work of Zamecnik and Stephenson (3, 4) used normal oligodeoxynucleotides, recent research has focused on derivatives (Fig. 1 ) that have certain desirable features, including nuclease resistance and rapid transport into cells (5-8). Generally these oligomers appear to function by inhibiting translation and splicing, but other inactivation mechanisms have also been found (9) .
During studies with oligodeoxynucleotides as inhibitors of human immunodeficiency virus type 1 (HIV-1), Matsukura et al. discovered that phosphorothioate oligodeoxycytidines exhibited potent antiviral activity (10); in these oligomers, one of the nonbridging oxygens at each linkage in oligodeoxycytidine, (dC)", has been replaced with sulfur, and individual oligomers are designated S(dC),. Inhibition of HIV-1 reverse transcriptase (RT) (11) or other steps in its life cycle such as binding, fusion, and entry (5, 10) were suggested as possible sites of action. Subsequent studies corroborated these observations and demonstrated that phosphorothioates are more effective than phosphoramidates and methylphosphonates as sequence-nonspecific inhibitors of HIV-1 replication (12) .
These developments prompted us to examine oligodeoxycytidine analogs bearing one or more phosphorodithioate linkages ( Fig. 1) as potential inhibitors of HIV-1 activity. This analog (13) (14) (15) (16) (17) (18) (19) (20) (25, 26) was a gift of S. Hughes (National Cancer Institute).
Inhibition of Other DNA Polymerases. Experimental analyses were essentially identical to those described for HIV-1 RT. Purified calf thymus a polymerase (Pol a) was a gift of R. Kuchta (University of Colorado), avian myeloblastosis virus (AMV) RT was from Life Sciences (St. Petersburg, Abbreviations: (dC)", oligodeoxycytidine of n nucleotides; S(dC)n, phosphorothioate analog of(dC),; S2(dC)", phosphorodithioate analog of (dC)"; HIV-1, human immunodeficiency virus type 1; RT, reverse transcriptase; AMV, avian myeloblastosis virus; Pol I, DNA polymerase I; Pol a, a polymerase. §To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. FL), and the Klenow fragment of Escherichia coli DNA polymerase I (Pol I) was from United States Biochemical. Enzyme concentrations were identical in all cases (10 nM (28) . Our initial investigations focused on the inhibitory effects of phosphorodithioate DNA analogs on the DNA-dependent DNA polymerase activity of recombinant HIV-1 RT (25, 26) . A synthetic heteropolymer primer-template system was designed in which a primer anneals to the complementary sequence at the 3' end of the template. This substrate was recognized by HIV-1 RT with high affinity (Km = 0. 13 ,uM) and provided an easily quantitated system for measuring DNA polymerase activity in the presence of oligodeoxynucleotide inhibitors.
In a first set of experiments (Fig. 2a) a per residue basis vs. phosphorodithioate oligomer length, the curve fits an exponential decay (data not shown). This indicates a law of diminishing return for dithioate oligomers beyond a certain length (12-14 nucleotides). In contrast, the largest increment in inhibition for thioate oligomers occurred in going from a 15-mer to a 28-mer. So whereas phosphorothioate oligomers of greater length are required for potent inhibition, relatively short phosphorodithioate oligomers are effective inhibitors.
Our attention turned to viral lysates to ensure that phosphorodithioate analogs had inhibitory properties against the RNA-dependent DNA polymerase activity of the p66-pSi heterodimer found in virusoids. The results (Fig. 2c) reveal that the phosphorodithioate dodecamer, S2(dC)12, is an effective inhibitor of HIV-1 RT in these lysates under conditions where the thioate analog of the same length is unable to alter activity even at the highest oligomer concentration tested. These observations mimic results with recombinant HIV-1 RT as reported in Fig. 2a and b and confirm the conclusion that relatively short phosphorodithioate oligomers are potent inhibitors of this enzyme.
Inhibition of Other DNA Polymerases. To complete the RT inhibition analysis, the effect of these oligodeoxycytidines on other DNA polymerases was studied (Table 2) . AMV RT was strongly inhibited by S2(dC)14 but not S(dC)15. Inhibition of the Klenow Pol I fragment was also examined. Here S2(dC)14 was less effective at inhibiting the Klenow polymerase than the HIV-1 RT by a factor of about 20, but for S(dC)15, this factor (the selectivity index) was only 8. Finally, the inhibitory properties against calf thymus Pol a were examined. Both the phosphorothioate and phosphorodithioate analogs of oligodeoxycytidine are good inhibitors with selectivity (Fig. 3a) .
Comparison with the thioate dodecamer shows that the dithioate is the more potent inhibitor. If one notes either the concentration at which 50% of the syncytia are inhibited or at which nearly all syncytia are eliminated, the dithioate oligomer is about 4-fold more effective.
Inhibition of HIV-1 Replication. The effect of phosphorothioate and phosphorodithioate oligodeoxycytidine dodecamers, S(dC)12 and S2(dC)12, on infection of target cells by HIV-i was also examined. In the first experiments, target CEM cells were infected with HIV-1 in the presence of oligomer. After infection the cells were washed to remove excess oligomer and replated without oligomer to avoid fortuitous RT inhibitory effects by the dithioate oligomer. S2dC12 was found to protect cells against infection by HIV-1 (Fig. 3b) , as a strong antiviral effect was observed at 1.25 AM; by 2.5 ,uM, this oligomer appeared to suppress infection of target cells. In contrast, S(dC)12 exhibited little inhibitory effect even at 10 ,M, which suggests that phosphorothioate oligomers of greater length are required to observe antiviral effects in the 1-2 ,uM range (10, 32) . To (Fig. 4) (10) .
Both S2(dC)12 and S2(dC)14 appeared to exert a cytoprotective effect on cells infected de novo with HIV-1. S2(dC)12 substantially blocked HIV-1 infection at 3 ,uM (Fig. 4a) , but at 0.3 p.M the cytoprotective effect was marginal. For S2dC14 (Fig. 4b) , strong anti-HIV activity was observed from 0.5 ,uM to 1 ,uM. As expected (10) , the S(dC)28 was also cytoprotective in this concentration range (0.5-3 p.M). These phosphorothioate oligomers also exert their cytoprotective effect at concentrations well below levels at which significant cytotoxicity occurs. Even at the highest concentrations tested (10 ,uM), the cytotoxicity of S2(dC)12 and S2(dC)14 was similar to that of S(dC)28, and in all cases the effect was marginal (25-35% loss in cell number).
DISCUSSION
These results suggest that phosphorodithioate DNA analogs should be further investigated as a potential therapeutic agent necessarily demonstrate that the cytoprotective effect of phosphorodithioate oligomers is due to inhibition of reverse transcriptase. The results of the syncytia formation assays indicate that these oligomers may exert an inhibitory effect at the cell surface. However, since the relative inhibitory activity of dithioate oligomer compared with its thioate homolog in the cell-free infection assay is greater than that observed in the syncytia formation assay (Fig. 3) , dithioate oligomers may exert antiretroviral effects at several stages in the infection process. These results indicate that dithioate DNA analogs may protect cells against HIV infection by multiple mechanisms-a possibility that could enhance their potential therapeutic value. The enhanced antiviral activity of relatively short phosphorodithioate oligomers is particularly exciting for two reasons. First, shorter oligomers are more efficiently transported across cell membranes (33) . Second, as one needs to perform fewer synthetic couplings to produce a potent inhibitor, phosphorodithioate analogs of reduced length represent a more feasible class of potential therapeutic oligonucleotides.
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